TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04353544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed cord clamping
Description: delayed cord clamping
Study: NCT02799472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Capsule, tablet or liquid administered orally or as SC injection.
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo
Study: NCT04353544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: delayed cord clamping
Study: NCT02622412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-professional breathlessness service (MBS)
Description: Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
Study: NCT02622412

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed MBS Intervention
Description: Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
Study: NCT01744379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Study: NCT04177264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipito-Atlantal Decompression (OA DC)
Description: The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Occipito-Atlantal Decompression (Sham OA DC)
Description: The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splenic Lymphatic Pump Technique (SpLPT)
Description: With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
Study: NCT01744379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03879525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR-based-interventional method
Description: Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based-standard method
Description: Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
Study: NCT02073448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK530G
Study: NCT02799472

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Capsule, tablet or liquid administered orally or as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic (or folinic) acid
Description: Capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic (or folinic) acid
Description: Capsule, tablet or liquid and will be administered orally.
Study: NCT04302376

Intervention type: DIAGNOSTIC_TEST
Intervention: Cather-related thrombosis ultrasonography
Description: Doppler and compression ultrasound to detect catheter-related thrombosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Cather-related thrombosis ultrasonography
Description: Doppler and compression ultrasound to detect catheter-related thrombosis
Study: NCT04067401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingman Connect
Description: Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
Study: NCT01815528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10
Study: NCT01515462

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-103
Description: OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
Study: NCT01547026

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Intentions
Description: In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
Study: NCT01905930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCM Cervical Disc
Description: Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Description: Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
Study: NCT00873236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-2a
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-2a
Description: Given SC
Study: NCT03569696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
Study: NCT03035305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based Nutrient Supplement (LNS)
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~* For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine

Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal malaria chemoprevention
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Study: NCT02893306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
Study: NCT00643123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300-600 mg/day over a 6 week period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study: NCT02922894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute episodic hypoxia
Description: The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Supplemental oxygen therapy for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 100mg before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One placebo pill before-bedtime

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Room air will be administered instead of episodic hypoxia or supplemental oxygen..

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Room air will be administered instead of episodic hypoxia or supplemental oxygen..
Study: NCT04116749

Intervention type: OTHER
Intervention: Water
Description: Drink water freely until 2 hours before anesthesia.

Intervention type: OTHER
Intervention: Water
Description: Drink water freely until 2 hours before anesthesia.
Study: NCT01417052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg LX3305 QD
Description: 50 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg LX3305 QD
Description: 100 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg LX3305 QD
Description: 150 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg LX3305 QD
Description: 200 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX3305 QD
Description: 250 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX3305 QD
Description: 300 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX3305 QD
Description: 400 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX3305 BID
Description: 250 mg LX3305 twice daily in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg LX3305 QD
Description: 500 mg LX3305 once daily in capsule form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing in capsule form
Study: NCT04177264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splenic Lymphatic Pump Technique (SpLPT)
Description: With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Splenic Lymphatic Pump Technique (Sham SpLPT)
Description: With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Splenic Lymphatic Pump Technique (Sham SpLPT)
Description: With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
Study: NCT02015091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
Study: NCT02267057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
Study: NCT03748511

Intervention type: OTHER
Intervention: fibroscan and stool sample
Description: patients undergo ultrasaound (fibroscan) in order to stage the liver disease.

Intervention type: OTHER
Intervention: fibroscan and stool sample
Description: patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
Study: NCT02267057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
Study: NCT03748511

Intervention type: OTHER
Intervention: fibroscan and stool sample
Description: patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
Study: NCT02150200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shorter hospitalization stay

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Study: NCT02073448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD0271
Study: NCT01438788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
Study: NCT01386996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose
Study: NCT02073448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD1579
Study: NCT00936754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed powder
Description: 500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
Study: NCT02267057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol placebo
Description: Paracetamol placebo tablets produced by Kragerø tablettproduksjon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine placebo
Description: Buprenorphine transdermal system placebo produced by Mundipharma.
Study: NCT01813461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled prodrug isavuconazonium sulfate
Description: oral
Study: NCT00759148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
Description: Eye drops
Study: NCT01386996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler forte
Description: 2 inhalations as a single dose
Study: NCT00759148

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin AF Vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT00861783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan and ON 01910.Na
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and ON 01910.Na
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling.
Study: NCT02137083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 D2 every 21 days
Study: NCT01386996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler forte
Description: 2 inhalations as a single dose
Study: NCT02137083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 D2 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg D1, D15, D29, D57, every 28 days later
Study: NCT03182257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7579
Description: ONO-7579 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7579
Description: ONO-7579 Tablets
Study: NCT03819725

Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose monitoring
Description: FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
Study: NCT01824615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5mg everyday from D1-D28
Study: NCT00723099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo umbilical cord blood transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV